Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
5-4-2011

Incidence of symptomatic venous thromboembolism in oncologic
patients undergoing lower-extremity endoprosthetic arthroplasty
Brandon A. Ramo
Vanderbilt Orthopaedic Institute

Anthony M. Griffin
University Musculoskeletal Oncology Unit at Mount Sinai Hospital

Corey S. Gill
Washington University School of Medicine in St. Louis

Douglas J. McDonald
Washington University School of Medicine in St. Louis

Jay S. Wunder
University Musculoskeletal Oncology Unit at Mount Sinai Hospital

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Ramo, Brandon A.; Griffin, Anthony M.; Gill, Corey S.; McDonald, Douglas J.; Wunder, Jay S.; Ferguson,
Peter; Bell, Robert S.; Phillips, Sharon E.; Schwartz, Herbert S.; and Holt, Ginger E., ,"Incidence of
symptomatic venous thromboembolism in oncologic patients undergoing lower-extremity endoprosthetic
arthroplasty." The Journal of Bone and Joint Surgery. 93,9. 847-854. (2011).
https://digitalcommons.wustl.edu/open_access_pubs/954

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Brandon A. Ramo, Anthony M. Griffin, Corey S. Gill, Douglas J. McDonald, Jay S. Wunder, Peter Ferguson,
Robert S. Bell, Sharon E. Phillips, Herbert S. Schwartz, and Ginger E. Holt

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/954

847
C OPYRIGHT Ó 2011

BY

T HE J OURNAL

OF

B ONE

AND J OINT

S URGERY, I NCORPORATED

Incidence of Symptomatic Venous
Thromboembolism in Oncologic
Patients Undergoing Lower-Extremity
Endoprosthetic Arthroplasty
By Brandon A. Ramo, MD, Anthony M. Griffin, MSc, Corey S. Gill, MD, Douglas J. McDonald, MD, Jay S. Wunder, MD,
Peter Ferguson, MD, Robert S. Bell, MD, Sharon E. Phillips, MSPH, Herbert S. Schwartz, MD, and Ginger E. Holt, MD
Investigation performed at Vanderbilt Orthopaedic Institute, Nashville, Tennessee

Background: As both cancer and major orthopaedic surgery are risk factors for venous thromboembolism, patients
undergoing lower-extremity oncologic endoprosthetic arthroplasty for neoplastic processes are at substantial risk of the
development of symptomatic venous thromboembolism. Therefore, the primary purpose of this study was to determine
the incidence of symptomatic venous thromboembolism in patients undergoing lower-extremity oncologic endoprosthetic
arthroplasty. Secondary purposes were to assess whether chemoprophylaxis influenced the incidence of venous
thromboembolism, surgical complications, or the incidence of local sarcoma recurrence. We also sought to determine
whether any known risk factors for venous thromboembolism could be identified in this patient population.
Methods: We performed a retrospective comparative review of 423 patients who had undergone mega-endoprosthetic
reconstruction following cancer resection. Univariate analysis was used to assess the association between chemoprophylaxis and the incidence of venous thromboembolism, to postulate the surgical complications associated with chemoprophylaxis, and to assess the rate of recurrence of local sarcoma as well the association between risk factors and
venous thromboembolism.
Results: Seventeen patients (4.0%) (95% confidence interval: 2.5% to 6.3%) had a venous thromboembolic event, ten
with deep venous thrombosis and seven with nonfatal pulmonary embolism. Risk factors and chemoprophylactic regimens were not statistically associated with the occurrence of venous thromboembolism.
Conclusions: The incidence of symptomatic venous thromboembolism in our group of cancer patients who underwent
lower-extremity endoprosthetic arthroplasty was lower than anticipated. A significant difference was not identified between the use of any or no chemoprophylactic agent and the incidence of venous thromboembolism or complication rates.
No risk factors were associated with the incidence of symptomatic venous thromboembolism.
Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.

T

he role of anticoagulation in the management of patients
undergoing lower-extremity total joint arthroplasty has
become more defined; however, its role in limb-salvage
surgery remains unclear1-6. Included in limb-salvage surgical
procedures is the use of oncologic endoprostheses (Fig. 1),
which are being employed with increasing frequency following
massive bone resections for the treatment of cancer.
Cancer patients undergoing surgery have been shown to
have a significantly higher risk of postoperative venous throm-

boembolism, deep venous thrombosis, and pulmonary embolism and as much as three times the likelihood of having a fatal
pulmonary embolism as compared with the likelihood in patients who do not have cancer 4-6 . Cancer patients who have
symptomatic venous thromboembolism have a higher mortality rate7. Major orthopaedic surgery is a significant risk
factor and has an estimated odds ratio of ten to twenty with
regard to venous thromboembolism3,8-11. Patients with an increased total number of risk factors may incur a greater indi-
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Fig. 1

Representative anteroposterior radiographs of endoprostheses that were implanted after tumor resection in the proximal part of the femur
(image at left), distal part of the femur (image in center), and proximal part of the tibia (image at right).

vidual risk of venous thromboembolism3,8-11. It was therefore
postulated that cancer patients who undergo oncologic endoprosthetic arthroplasty may be at a substantially higher risk of
the development of symptomatic venous thromboembolism.
Many patients undergoing limb salvage have historically not
received routine chemoprophylaxis for fear of increased bleeding and subsequent wound complications12. Since sarcomas are
highly implantable, hematomas as a result of aggressive anticoagulation may lead to increased rates of local recurrence5.
Centers performing large volumes of lower-extremity bonetumor resections have shown no higher incidences of symptomatic venous thromboembolism in patients who received
no chemoprophylaxis than the incidence seen in other lowerextremity arthroplasty populations13-15. This knowledge leads
one to question the routine use of chemoprophylaxis in this
population at high risk of local recurrence, wound complications, and infection.
The purpose of this study was to determine the incidence
of symptomatic venous thromboembolism for patients undergoing lower-extremity oncologic endoprosthetic arthroplasty.
We compared this group with patients undergoing elective total
hip and knee arthroplasty. As secondary goals, we sought to
examine the effects that different chemoprophylactic agents had
on the occurrence of symptomatic venous thromboembolism,

on complication rates, and on local recurrence of sarcoma.
Furthermore, we attempted to identify any risk factors for
symptomatic venous thromboembolism that could potentially aid in establishing a protocol for the selective use of
chemoprophylaxis.
Materials and Methods

T

hree tertiary referral centers for musculoskeletal oncology participated in
this retrospective comparative study. Institutional review board approval
was obtained at each institution. The study group consisted of all patients who
were seventeen years of age or older and had a diagnosis of cancer that had been
treated with primary or revision lower-extremity endoprosthetic joint arthroplasty sometime between 1989 and 2007. Indications for the surgical
procedure were malignant tumors requiring wide resection of the proximal part
of the femur, distal part of the femur, or proximal part of the tibia and resulting
in inadequate remaining articulating bone for reconstruction without the
use of a prosthesis. Age seventeen was chosen because this is a common age
for musculoskeletal maturity and is the age at which patients are treated as
adults at our institutions.
Historically, the rate of symptomatic venous thromboembolism in the
population of patients undergoing elective total joint arthroplasty with
9,16-21
chemoprophylaxis is estimated to be approximately 3%
. A doubling of this
rate was chosen to represent a number that the authors believed would be a
clinically significant difference between our population and the historical
control. A power analysis indicated that a minimum sample size of 359 patients
was needed to detect this clinically significant difference with 80% power with
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use of a continuity-corrected chi-square statistic or Fisher exact test at a 5%
significance level. Assumptions included (1) that all patients with symptomatic
venous thromboembolism would be captured in retrospective review of the
charts, and (2) that this represents the true rate of symptomatic venous
thromboembolism.
Review of the databases from our three institutions yielded 561 consecutive patients who had undergone limb salvage with use of a lower-extremity
oncologic endoprosthesis. One hundred and thirty-eight patients were excluded
for reasons that included an age of less than seventeen years (forty-four patients), a
noncancer diagnosis (seventy-six patients), and incomplete medical records or
inadequate follow-up of less than six weeks (eighteen patients), yielding a final
study number of 423 patients.
A review of the medical records for each patient was performed to extract
pertinent demographic data, including diagnosis, age, sex, and body mass index. Our primary outcome variable was any symptomatic occurrence of
venous thromboembolism within six weeks of the surgery. Our definition of
venous thromboembolism was any deep venous thrombosis or pulmonary
embolism confirmed by an imaging modality, including a positive result on a
computed tomography scan of the chest, high-probability ventilation-perfusion
scan, venographic study, or duplex ultrasound. Six weeks was used as the end
point for time because we believe that any venous thromboembolism occurring
after this point should not be attributed to the surgery.
We identified four postoperative anticoagulation regimens, which were the
basis of our four groups: (1) no agent, (2) a low-molecular-weight heparin, (3)
warfarin, and (4) an alternative regimen. We chose to combine different lowmolecular-weight heparins (including enoxaparin and dalteparin) into a
single group. In general, patients treated in the low-molecular-weight heparin
and warfarin groups received ten to twenty-one days of anticoagulation. Group 4
consisted of several alternative prophylactic regimens, which included subcutaneous heparin used alone, aspirin used alone, and several drugs used in
various combinations. For example, several patients received short-term
anticoagulation with a low-molecular-weight heparin for three to five days while
they were an inpatient, with conversion to aspirin or no agent at the time of
discharge. Mechanical prophylaxis was routinely employed in all patients at all
three institutions during the study period; hence, mechanical prophylaxis was
not analyzed as a variable.
We identified any complications occurring in the early postoperative
period that might be attributable to anticoagulation, including superficial infection; deep infection; superficial wound complications, such as a dehiscence; and deep wound complications, defined as hematoma or seroma
requiring surgical intervention. Major bleeding was defined as transfusion of
greater than five units of packed red blood cells postoperatively, a gastrointestinal bleed, or a retroperitoneal hematoma. We also identified local recurrences for all sarcomas with a minimum of two years of follow-up.
We identified and recorded known and potential risk factors for
venous thromboembolism, including a history of venous thromboembolism, pathologic fracture, sex, obesity (body mass index >30 kg/m2), anatomic
location of procedure, residence in an institution, advanced age (greater than
seventy years), history of cerebrovascular accident, history of a hypercoagulable
state, tamoxifen use, oral contraceptive use, chronic renal insufficiency, or pres7,22-25
ence of a central venous catheter
.
Descriptive statistics were used to explore all variables and to compute the
incidence of symptomatic venous thromboembolism. The Wilcoxon rank-sum
test for continuous variables and the Fisher exact test for dichotomous variables
were used to examine the association between risk factors (age, sex, type of cancer,
pathologic fracture, obesity, location of procedure [hip vs. knee]) and incidence
of symptomatic venous thromboembolism. The Fisher exact test was used to
examine the association between (1) prophylactic regimen and incidence of
venous thromboembolism, (2) prophylactic regimen and specific complications
(major bleeding, superficial and deep infections, or superficial and deep wound
complications), and (3) prophylactic regimen and local recurrence (including only
patients with sarcoma who had a minimum follow-up of two years). A multiple
variable logistic regression analysis was used to examine the association between
prophylactic regimen and the presence of one or more complications, controlling for
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age, body mass index, fracture, and location of surgery (hip vs. knee). All statistical
tests were two-tailed, with a p value of 0.05 or less considered significant.

Source of Funding
There was no external source of funding for this study.

Results
our hundred and twenty-three patients underwent reconstruction with an endoprosthesis following resection of a
bone tumor and had greater than six weeks of follow-up. There
were 341 sarcomas and eighty-two carcinomas (Table I). There

F

TABLE I Cancer Type
Type of Cancer
Sarcoma

Number of Patients
341

Osteosarcoma

158

Chondrosarcoma

69

Malignant fibrous histiosarcoma

27

Leiomyosarcoma

25

Ewing sarcoma
Fibrosarcoma

15
10

Angiosarcoma

7

Synovial sarcoma

5

Sarcoma not otherwise specified

5

Hemangiopericytoma

3

Malignant giant-cell tumor

3

Neurosarcoma

3

Spindle-cell sarcoma
Other*

2
9

Adenocarcinoma

58

Breast

17

Kidney

16

Prostate

6

Lung

4

Colon

3

Thyroid

2

Gastrointestinal tract (primary)
Uterus

5
1

Bladder

1

Unknown primary

3

Multiple myeloma

9

Lymphoma

6

Squamous-cell carcinoma

5

Melanoma

4

Total

423

*Sarcomas with ‘‘other’’ diagnoses include 1 each of liposarcoma, follicular dendritic-cell sarcoma, chondromatosis, malignant
granular-cell tumor, peripheral-nerve-sheath tumor, postradiation
sarcoma, alveolar soft-part sarcoma, telangiectatic sarcoma, and
undifferentiated sarcoma.
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TABLE II Distribution of Endoprostheses and Occurrence of Venous Thromboembolism by Location*
Endoprosthetic Knee (N = 269)

Endoprosthetic Hip (N = 142)

Total Femur (N = 12)

Venous thromboembolisms

8 (3.0%; CI, 1.5 to 5.8)

8 (5.6%; CI, 2.9 to 10.7)

1 (8.3%; CI, 1.5 to 35.4)

Deep venous thrombosis†

3 (1.5%; CI, 0.6 to 3.8)

6 (4.2%; CI, 2.0 to 8.9)

1 (12.5%)

Pulmonary embolism†

5 (1.5%; CI, 0.6 to 3.8)

2 (1.4%; CI, 0.4 to 5.0)

0 (0%)

*CI = 95% confidence interval. †Two of the patients (one hip and one knee) with pulmonary embolism had concurrent evidence of deep venous
thrombosis on Doppler examination but were included only in the pulmonary embolism group.

were 269 endoprosthetic procedures in the knee (distal part of
the femur or proximal part of the tibia) and 142 in the proximal
part of the femur, and there were twelve total femoral reconstructions (Table II).
Incidence of Symptomatic Venous Thromboembolism
Of the 423 cancer patients who underwent endoprosthetic arthroplasty, seventeen patients (4.0%) had a symptomatic venous thromboembolism (95% confidence interval, 2.5% to
6.3%). Of these, ten had a deep venous thrombosis (2.4%)
(95% confidence interval, 1.3% to 4.3%) and seven had a
pulmonary embolism (1.7%) (95% confidence interval, 0.8%

to 3.4%). Two of the patients with a pulmonary embolism
had concurrent evidence of deep venous thrombosis on
Doppler examination and were included only in the pulmonary embolism group. There were no known occurrences
of fatal pulmonary embolism. The characteristics of the
seventeen patients with symptomatic venous thromboembolism are listed in Table III.
Symptomatic Venous Thromboembolism by
Chemoprophylactic Regimen
Three hundred and twenty patients (76%) received some form
of chemoprophylaxis, and 103 (24%) received none. Table IV

TABLE III Patients with Venous Thromboembolism*
Age (yr)

Sex

Diagnosis

Outcome

Location of Tumor

Hip or Knee

Prophylactic Regimen

58

M

Chondrosarcoma

DVT

PF

Hip

None

30

F

Chondrosarcoma

DVT

PF

Hip

Warfarin

36

M

Osteosarcoma

DVT

DF

Knee

Warfarin

67

M

Chondrosarcoma

PE

PF

Hip

None

80

F

Breast cancer; pathologic
fracture

DVT

PF

Hip

Warfarin

70

M

Chondrosarcoma

DVT/PE

PF

Hip

Enoxaparin followed
by warfarin

32

F

Osteosarcoma

DVT

DF

Knee

Aspirin

77

M

Osteosarcoma

DVT

PF

Hip

Warfarin

56

M

Melanoma, metastatic

PE

DF

Knee

Warfarin

62

M

SCC, metastatic

PE

PT

Knee

None

31

M

Chondrosarcoma

DVT

PF

Hip

Warfarin

33

M

Osteosarcoma

DVT

PF

Hip

Heparin

55

M

Chondrosarcoma

DVT/PE

PT

Knee

Dalteparin

18

M

Osteosarcoma

PE

PT

Knee

Dalteparin

31

M

Osteosarcoma

DVT

Femur

Total

Dalteparin

53

F

Malignant fibrous
histiocytoma

PE

DF

Knee

Enoxaparin

59

F

Malignant fibrous
histiocytoma

DVT

DF

Knee

Warfarin, heparin, IVC filter

*DVT = deep venous thrombosis, PF = proximal part of the femur, DF = distal part of the femur, PE = pulmonary embolism, SCC = squamous-cell
carcinoma, PT = proximal part of the tibia, and IVC = inferior vena cava.
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TABLE IV Incidence of Venous Thromboembolism by Chemoprophylactic Regimen*
No Prophylaxis
(N = 103)

Warfarin (N = 115)

Low-Molecular-Weight
Heparin (N = 147)

Other (N = 58)

Total No. of
Patients (N = 423)

Venous
thromboemboli

3 (2.9%, CI: 1.0% to 8.2%)

6 (5.2%, CI: 2.4% to 10.9%)

4 (2.7%, CI: 1.1% to 6.8%)

4 (6.9%, CI: 2.7% to 16.4%)

17 (4.0%, CI: 2.5% to 6.3%)

Deep venous
thrombosis

1 (1.0%, CI: 0.2% to 5.3%)

5 (4.3%, CI: 1.9% to 9.8%)

2 (1.4%, CI: 0.4% to 4.8%)

3 (5.2%, CI: 1.8% to 14.1%)

10 (2.4%, CI: 1.3% to 4.3%)

Pulmonary
embolism

2 (1.9%, CI: 0.5% to 6.8%)

1 (0.9%, CI: 0.2% to 4.8%)

2 (1.4%, CI: 0.4% to 4.8%)

1 (1.7%, CI: 0.3% to 9.1%)

7 (1.6%, CI: 0.8% to 3.4%)

*CI = 95% confidence interval.

TABLE V Complications by Chemoprophylactic Regimen*
No Prophylaxis
(N = 103)

Warfarin (N = 115)

Low-Molecular-Weight
Heparin (N = 147)

Other (N = 58)

Complications

13 (12.6%, CI: 7.5% to 20.4%)

16 (13.9%, CI: 8.7% to 21.4%)

Superficial
wound
problem

2 (1.9%, CI: 0.5% to 6.8%)

4 (3.5%, CI: 1.4% to 8.6%)

12 (8.2%, CI: 4.7% to 13.7%)

28 (19.0%, CI: 13.5% to 26.2%)

13 (22.4%, CI: 13.6% to 34.7%)
3 (5.2%, CI: 1.8% to 14.1%)

21 (5.0%, CI: 3.3% to 7.5%)

Deep wound
problem

3 (2.9%, CI: 1.0% to 8.2%)

2 (1.7%, CI: 0.5% to 6.1%)

1 (0.7%, CI: 0.1% to 3.8%)

1 (1.7%, CI: 0.3% to 9.1%)

7 (1.6%, CI: 0.8% to 3.3%)

Superficial
infection

1 (0.9%, CI: 0.2% to 5.3%)

1 (0.9%, CI: 0.2% to 4.8%)

2 (1.4%, CI: 0.4% to 4.8%)

2 (3.4%, CI: 1.0% to 11.7%)

6 (1.4%, CI: 0.7% to 3.1%)

Deep
infection

6 (5.8%, CI: 2.7% to 12.1%)

8 (7.0%, CI: 3.6% to 13.1%)

11 (7.5%, CI: 4.2% to 12.9%)

4 (6.9%, CI: 2.7% to 16.4%)

29 (6.9%, CI: 4.8% to 9.7%)

Major
bleeding

1 (0.9%, CI: 0.2% to 5.3%)

1 (0.9%, CI: 0.2% to 4.8%)

2 (1.4%, CI: 0.4% to 4.8%)

3 (5.2%, CI: 1.8% to 14.1%)

Total Patients (N = 423)
70 (16.5%, CI: 13.3% to 20.4%)

7 (1.6%, CI: 0.8% to 3.74%)

*CI = 95% confidence interval.

TABLE VI Sarcoma Local Recurrence Rates by Chemoprophylactic Regimen After a Minimum of Two Years of Follow-up*

Local
recurrence

No Prophylaxis
(N = 88)

Warfarin (N = 82)

Low-Molecular-Weight
Heparin (N = 94)

Other (N = 32)

Total Patients (N = 296)

11 (12.5%, CI: 7.1% to 21.0%)

5 (6.1%, CI: 2.6% to 13.5%)

2 (2.1%, CI: 0.6% to 7.4%)

6 (18.8%, CI: 8.9% to 35.3%)

24 (8.1%, CI: 5.5% to 11.8%)

*CI = 95% confidence interval.

demonstrates the number of symptomatic venous thromboembolism events by chemoprophylactic regimen. Three of 103
patients who received no prophylaxis had a venous thromboembolism event, whereas six of 115 patients who received
Coumadin (warfarin), four of 147 patients who received lowmolecular-weight heparin and four of fifty-eight patients who
received an alternative regimen had venous thromboembolism
events. These results did not achieve a significant difference
(p = 0.245) on the basis of Fisher exact testing.
Complication Rates by Chemoprophylactic Regimen
There were no differences in specific complication rates by
chemoprophylactic regimen on the basis of univariate

analyses (Table V). Thirty-five patients (8.3%) had an infection, usually deep; twenty-eight patients (6.6%) had wound
complications not attributable to infection; and seven patients (1.7%) had a major bleeding complication including
a gastrointestinal bleed, cerebrovascular accident, or large
hematoma requiring surgical debridement. The overall
complication rate was 16.5% (seventy of 423 patients). Logistic regression analysis found no statistical association
between chemoprophylactic regimen and presence of a
complication; however, patients undergoing hip compared
with knee arthroplasty were less likely to have a complication
after surgery (odds ratio, 0.30; 95% confidence interval, 0.16
to 0.56).

852
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
V O LU M E 93 -A N U M B E R 9 M AY 4, 2 011
d

d

d

Local Recurrence by Chemoprophylactic Regimen
Among sarcoma patients with at least two years of follow-up,
statistical differences were noted in local recurrence on the basis
of chemoprophylactic regimen (Fisher exact test p = 0.0049)
(Table VI). The total number of local recurrences for 296
sarcoma patients was twenty-four, representing a local recurrence rate of 8.1%. Five (6.1%) of eighty-two sarcoma patients
treated with Coumadin (warfarin) and two (2.1%) of ninetyfour sarcoma patients treated with low-molecular-weight
heparin had a local recurrence, in contrast to eleven (12.5%) of
eighty-eight and six (18.8%) of thirty-two patients who were
treated with no prophylaxis or a nontraditional form of prophylaxis, respectively, and had local recurrence.
Symptomatic Venous Thromboembolism and Risk Factors
The multiple risk factors for venous thromboembolism were
evaluated with use of univariate analysis, and none were statistically associated with the incidence of symptomatic venous
thromboembolism in our patient population.
Discussion
e found a low overall incidence of symptomatic venous
thromboembolism (4%) with no fatal pulmonary emboli, which does not appear to be substantially different from
rates seen in elective total hip and knee arthroplasty populations.
We did not demonstrate that any one prophylactic regimen
provided better protection than another against symptomatic
venous thromboembolism, although we acknowledge an ostensible regimen selection bias between cohorts on the basis
of tumor, resection, and reconstruction type. This finding is not
surprising, given the lack of a definitive answer in the substantially
larger patient population that has been reported in the elective
arthroplasty literature, in which the overall risk of symptomatic venous thromboembolism is approximately 3%9,16-21.
Studies addressing venous thromboembolism in orthopaedic oncology patients are rare. Lin et al. reported a prevalence of asymptomatic deep venous thrombosis of 14% and
symptomatic pulmonary embolism of 0.6% in 169 cancer
patients who were undergoing a variety of orthopaedic lowerextremity surgical procedures, but further analysis is difficult
because of the heterogeneity of patients, diseases, and treatments, including multimodal anticoagulant regimens 4. The
same group later found an overall deep venous thrombosis rate
of 4% in cancer patients who were undergoing hip arthroplasty
for pathologic fractures or tumor resections along with lowmolecular-weight heparin as chemoprophylaxis6.
Mitchell et al. reported a venous thromboembolism rate
of 5.2% and a fatal pulmonary embolism rate of 0.4% in a
heterogeneous group of 252 patients with bone or soft-tissue
sarcomas who were undergoing a variety of orthopaedic procedures5. All thirteen patients with venous thromboembolism
had sarcoma of the hip or thigh, and two of thirty-one patients
undergoing endoprosthesis arthroplasty had a venous thromboembolism. Further, they found that the majority of venous
thromboembolism events actually occurred before definitive
limb-salvage surgery, implying that the procedure itself may
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not be the main risk factor. The Royal Orthopaedic Hospital
Oncology Service in Birmingham, United Kingdom, published
the results of 661 endoprosthetic replacements after ten years of
follow-up14. They noted a low (3.4% overall) incidence of venous thromboembolism, which was similar to that seen in our
group. The incidence of deep venous thrombosis was 1.1%,
whereas the incidence of pulmonary embolism accounted
for a higher percentage and was 2.3% 14 . Another recent
study of venous thromboembolism in arthroplasty patients, in
which a total venous thromboembolism rate of 3.5% was
demonstrated, showed via subgroup analysis that a history of
malignancy conferred a 4.2% risk of the development of venous
thromboembolism as compared with a prevalence of venous
thromboembolism of 1.65% in patients without a history of
malignancy8.
There is little evidence-based guidance for the orthopaedic oncologist whose patients fall into the category of having
a high risk of both bleeding and venous thromboembolism,
according to the guidelines of both the American Academy of
Orthopaedic Surgeons (AAOS) and the American College of
Chest Physicians (ACCP). The ACCP Prevention of Venous
Thromboembolism guidelines are inconclusive when applied to
orthopaedic oncology patients3. The ACCP strongly considers
most orthopaedic patients to be ‘‘high-risk,’’ and they recommend the use of low-molecular-weight heparin, fondaparinux,
or Coumadin (warfarin) for these patients. For cancer patients,
the ACCP guidelines recommend ‘‘aggressive thromboprophylaxis’’ that is based on the type of surgery. There are several
caveats to these recommendations, however. First, they note
that patients with ‘‘high venous thromboembolism risk plus
high bleeding risk’’ can be considered for mechanical prophylaxis alone. Second, there is a comment that descriptive
terms, such as ‘‘high bleeding risk,’’ are purposely left undefined to allow individual clinician interpretation. The AAOS
Guidelines Oversight Committee conducted an evidence-based
review of the literature and offered an alternative set of recommendations to the orthopaedic community in 20082. Their
recommendations with regard to patients undergoing limb
salvage or endoprosthetic arthroplasty indicate that aspirin,
Coumadin (warfarin), or no anticoagulant at all should be
considered for patients who are at high risk for venous thromboembolism or bleeding.
We hypothesized that patients who received anticoagulants would demonstrate more complications that could be
associated with anticoagulation, such as infections or wound
dehiscences. We were unable to demonstrate that any prophylactic regimen was associated with higher complication rates,
although we did note that complication rates were higher in
patients who had undergone knee surgery than they were in
patients who had undergone hip surgery. Our overall complication rates proved to be similar to those published in the largest
comparable series, again emphasizing that this is a patient
population already at high risk for complications that may be
aggravated by aggressive anticoagulation26. We were unable to
confirm these individual risk factors for deep venous thrombosis or pulmonary embolism in our patient population, al-
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though such confirmation might have been useful in the
creation of a selective-use protocol3,8-11.
There were several limitations to our study. It was retrospective and observational, covering two decades of operative
experience at multiple institutions. The use of chemoprophylactic agents was not randomized or standardized, and there
may have been some differences between patients who did not
receive prophylaxis and those who did. Further, multimodal
chemoprophylaxis protocols were employed. These limitations
reflect the current variability among orthopaedic surgeons in
the use of different chemoprophylactic agents and also reflect
the evolution in the use of these agents over the last few decades. The rarity of these limb-salvage surgical procedures, the
low prevalence of symptomatic venous thromboembolism,
and the availability of multimodal prophylaxis protocols
make a prospective trial unachievable. In the absence of a
large set of patients, we were forced to compare our findings
to a historical control, acknowledging differences in technical aspects of the limb-salvage procedures, such as operative
time, estimated blood loss, and the need for soft-tissue coverage. The authors acknowledge that the cancer ascertainment methods used for historical hip and knee arthroplasty
controls may be different than the methods that we used in
our patients.
In summary, the primary goal of this project was to provide a baseline incidence of symptomatic venous thromboembolism in oncologic patients undergoing lower-extremity
endoprosthetic arthroplasty. In this study, patients undergoing endoprosthetic arthroplasty for the treatment of cancer did
not have the extremely high incidence of symptomatic venous thromboembolism that we had anticipated, but our patients did have the high risks of wound complications and
infections that are common to this population. The authors
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continue to be concerned about the widespread use of panprophylactic protocols for the avoidance of venous thromboembolism, particularly in this complex group of patients in
whom multiple variables must be weighed regarding the potential benefits and risks of chemoprophylactic agents against
venous thromboembolism. n
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